RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Suzhou Alphamab Oncology and 3D Medicines of Shanghai have started China Phase III trials of their novel fusion anti-PD-L1 antibody in patients with bile tract carcinoma. The candidate is also in a China Phase II trial for MSI-H solid tumors. According to the companies, KN035 is a first-in-class PD-L1 single-domain antibody with the unique advantages of subcutaneous injection and good stability at room temperature. So far, more than 300 patients have participated in KN035 clinical trials in the United States, Japan and China.
Source: China Biotoday
